| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Rapport Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 47,807,62... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 |
| 21 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 |
| 07 Jan 2026 |
8-K: Other Events
Re: Securities Registered under Registration Statement on Form S-3 |
| 07 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures |
| 10 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 08 Sep 2025 |
8-K: Other Events
Effective September 8, 2025, the Company terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333-288444) (the “Registration Statement”) and related to the... |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
BOSTON and SAN DIEGO, September 8, 2025 — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025 |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Rapport Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 21, 2025, the record date for the Annual Meeting, there were 36,497,555 shares of the Company’s... |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders |
| 03 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
Disclaimer This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,... |
Loading...